Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study Evaluating the Safety and Tolerability of Intratumoral Administration of ORCA-010 in Treatment-Naïve Patients With Localized Prostate Cancer.

NCT04097002 is registered in ClinicalTrials.gov with Orca Therapeutics B.V. as lead sponsor.

NCT NCT04097002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04097002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study Evaluating the Safety and Tolerability of Intratumoral Administration of ORCA-010 in Treatment-Naïve Patients With Localized Prostate Cancer.
Lead sponsor
Orca Therapeutics B.V.
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 12, 2019
Completion date
December 31, 2024
Enrollment
24 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate